期刊
BIOMOLECULES
卷 13, 期 2, 页码 -出版社
MDPI
DOI: 10.3390/biom13020309
关键词
clinical trials; 5-HT6 receptor antagonist; avisetron; cerlapirdine; idalopirdine; intepirdine; landipirdine; latrepirdine; SAM-760; masupirdine; schizophrenia; Alzheimer's disease; dementia; neuropsychiatric symptoms; psychosis; agitation
Serotonin-6 (5-HT6) receptor, a G-protein-coupled receptor, plays a key role in the regulation of various functions in the nervous system. Clinical studies have shown that 5-HT6 receptor antagonists have potential in treating cognitive deficits associated with Alzheimer's disease (AD) and neuropsychiatric symptoms in dementia. However, the outcomes of phase 3 trials for these antagonists have been disappointing. Masupirdine, a selective 5-HT6 receptor antagonist, has shown promise in reducing agitation/aggression-like behaviors in animal models and may have potential benefits for agitation and psychosis in AD, but further trials are needed.
Serotonin (5-HT) plays an important role in the regulation of several basic functions of the central and peripheral nervous system. Among the 5-HT receptors, serotonin-6 (5-HT6) receptor has been an area of substantial research. 5-HT6 receptor is a G-protein-coupled receptor mediating its effects through diverse signaling pathways. Exceptional features of the receptors fueling drug discovery efforts include unique localization and specific distribution in the brain regions having a role in learning, memory, mood, and behavior, and the affinity of several clinically used psychotropic agents. Although non-clinical data suggest that both agonist and antagonist may have similar behavioral effects, most of the agents that entered clinical evaluation were antagonists. Schizophrenia was the initial target; more recently, cognitive deficits associated with Alzheimer's disease (AD) or other neurological disorders has been the target for clinically evaluated 5-HT6 receptor antagonists. Several 5-HT6 receptor antagonists (idalopirdine, intepirdine and latrepirdine) showed efficacy in alleviating cognitive deficits associated with AD in the proof-of-concept clinical studies; however, the outcomes of the subsequent phase 3 studies were largely disappointing. The observations from both non-clinical and clinical studies suggest that 5-HT6 receptor antagonists may have a role in the management of neuropsychiatric symptoms in dementia. Masupirdine, a selective 5-HT6 receptor antagonist, reduced agitation/aggression-like behaviors in animal models, and a post hoc analysis of a phase 2 trial suggested potential beneficial effects on agitation/aggression and psychosis in AD. This agent will be assessed in additional trials, and the outcome of the trials will inform the use of 5-HT6 receptor antagonists in the treatment of agitation in dementia of the Alzheimer's type.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据